Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine

Mohamed R. Akl, Poonam Nagpal, Nehad M. Ayoub, Sathyen A. Prabhu, Matthew Gliksman, Betty Tai, Ahmet Hatipoglu, Andre Goy and K. Stephen Suh _

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:28693-28715. https://doi.org/10.18632/oncotarget.4981

Metrics: PDF 3158 views  |   HTML 6372 views  |   ?  


Mohamed R. Akl1, Poonam Nagpal1, Nehad M. Ayoub2, Sathyen A. Prabhu1, Matthew Gliksman1, Betty Tai1, Ahmet Hatipoglu1, Andre Goy3 and K. Stephen Suh1

1 Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

2 Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan

3 Lymphoma Division, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Correspondence to:

K. Stephen Suh, email:

Keywords: syndecan, biomarker, cancer, personalized medicine, CD138

Received: May 27, 2015 Accepted: July 11, 2015 Published: July 22, 2015


Syndecan-1 (SDC1, CD138) is a key cell surface adhesion molecule essential for maintaining cell morphology and interaction with the surrounding microenvironment. Deregulation of SDC1 contributes to cancer progression by promoting cell proliferation, metastasis, invasion and angiogenesis, and is associated with relapse through chemoresistance. SDC1 expression level is also associated with responses to chemotherapy and with prognosis in multiple solid and hematological cancers, including multiple myeloma and Hodgkin lymphoma. At the tissue level, the expression levels of SDC1 and the released extracellular domain of SDC1 correlate with tumor malignancy, phenotype, and metastatic potential for both solid and hematological tumors in a tissue-specific manner. The SDC1 expression profile varies among cancer types, but the differential expression signatures between normal and cancer cells in epithelial and stromal compartments are directly associated with aggressiveness of tumors and patient’s clinical outcome and survival. Therefore, relevant biomarkers of SDC signaling may be useful for selecting patients that would most likely respond to a particular therapy at the time of diagnosis or perhaps for predicting relapse. In addition, the reciprocal expression signature of SDC between tumor epithelial and stromal compartments may have synergistic value for patient selection and the prediction of clinical outcome.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4981